Jana Wattar | Pharmacology | Women Researcher Award

Published on by Academic Achievements

Women Researcher Award

Jana K. Al Wattar
Lebanese International University,  Lebanon
Jana K. Al Wattar
Affiliation Lebanese International University
Country Lebanon
Scopus ID 56999102300
Documents 9
Citations 172
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Academic Achievements & Awards

Jana K. Al Wattar is a Lebanese pharmaceutical scientist, academic researcher, and Assistant Professor specializing in pharmaceutical sciences, nanotechnology-based drug delivery systems, and translational nanomedicine. Her research primarily focuses on smart lipid-based nanocarriers for cancer therapeutics and neurodegenerative disorders, with emphasis on enhancing therapeutic efficacy, improving drug bioavailability, and overcoming multidrug resistance mechanisms.[1]

Over more than a decade of academic and professional engagement, Dr. Al Wattar has contributed extensively to pharmaceutical education, interdisciplinary nanomedicine research, and international scientific collaboration. Her work integrates pharmaceutical technology, nanotechnology, biotechnology, and biomedical innovation through collaborative partnerships across Lebanon, the Gulf region, and international academic institutions.[2]

Abstract

Jana K. Al Wattar has established a distinguished research profile in pharmaceutical sciences with specialization in nanotechnology-based therapeutic delivery systems for oncology and neurological disorders. Her scientific contributions encompass the formulation, optimization, and characterization of smart nanocarriers, including nanovesicles, nanosponge systems, liposomal nanohybrids, electrohydrodynamic nanofibers, and stimuli-responsive drug delivery platforms.[3]

Her work demonstrates interdisciplinary integration of pharmaceutical technology, nanomedicine, biomaterials, and translational therapeutics. In addition to publishing in internationally recognized journals, she has actively contributed to scientific conferences, secured competitive research grants, supervised collaborative projects, and established institutional research partnerships across the Middle East and beyond.[4]

Keywords

Nanomedicine; Pharmaceutical Technology; Drug Delivery Systems; Lipid Nanocarriers; Cancer Therapeutics; Neurodegenerative Disorders; Smart Nanovesicles; Nanotechnology; Biomaterials; Pharmaceutical Biotechnology; Liposomal Systems; Targeted Drug Delivery; Tissue Engineering; Translational Medicine; Pharmaceutical Sciences

Introduction

Advances in nanotechnology and pharmaceutical sciences have transformed the development of targeted therapeutic systems for complex diseases including cancer and neurodegenerative disorders. Researchers in pharmaceutical nanotechnology contribute significantly to improving therapeutic outcomes through innovative drug delivery systems that enhance bioavailability, stability, specificity, and patient safety. Dr. Jana K. Al Wattar has contributed to this evolving field through sustained academic research focused on nanocarrier engineering, smart drug delivery systems, and translational pharmaceutical applications.[5]

Her research vision aims to establish a translational nanomedicine platform in the Levant region that addresses unmet therapeutic challenges associated with drug resistance, poor bioavailability, and targeted treatment delivery. Her academic and scientific activities demonstrate commitment to regional research development, scientific leadership, and interdisciplinary collaboration.

Research Profile

Dr. Al Wattar currently serves as a Full-time Assistant Professor in the Department of Pharmaceutical Sciences at Lebanese International University in Beirut, Lebanon. Her teaching portfolio includes pharmaceutics, dosage forms, pharmaceutical calculations, physical pharmacy, compounding laboratories, biotechnology laboratories, and pharmacy practice experience courses.

Her academic experience spans more than twelve years in higher education, during which she has contributed to undergraduate and postgraduate mentorship, pharmaceutical curriculum development, and scientific supervision. Prior to her current appointment, she served as Lecturer Assistant at Beirut Arab University and Instructor at Lebanese International University.

Her doctoral studies in Pharmaceutical Technology and Industrial Pharmacy at Beirut Arab University focused on innovative nanotechnology-based formulations and advanced pharmaceutical delivery systems. Her academic trajectory has consistently emphasized pharmaceutical innovation and translational therapeutic applications.

Research Contributions

Dr. Al Wattar has contributed substantially to nanomedicine research through development and optimization of advanced drug delivery systems. Her investigations focus on enhancing therapeutic efficacy while minimizing toxicity through rational nanocarrier design and smart pharmaceutical engineering strategies.

  • Development of lipid-based nanocarriers for targeted cancer therapeutics.
  • Optimization of nanovesicle systems for neurological and neuroinflammatory disorders.
  • Investigation of smart stimuli-responsive liposomal nanohybrid systems for theranostic applications.
  • Research on electrohydrodynamic atomization for fast-dissolving drug delivery systems.
  • Studies involving thymoquinone-loaded nanosystems for oxidative stress modulation and anticancer activity.
  • Collaborative interdisciplinary projects involving biomaterials, tissue engineering, and pharmaceutical biotechnology.

Her collaborative network extends across leading institutions in Lebanon, the United Arab Emirates, Jordan, and Egypt, demonstrating active international scientific engagement in pharmaceutical nanotechnology and translational biomedical sciences.

Publications

Jana K. Al Wattar has authored and co-authored numerous peer-reviewed publications in pharmaceutical sciences, nanomedicine, and drug delivery research. Her scholarly work focuses on lipid nanovesicles, smart nanocarriers, cancer therapeutics, neurodegenerative disorders, and pharmaceutical biotechnology, contributing to advancements in targeted drug delivery systems and translational pharmaceutical innovation.

Research Impact

Dr. Al Wattar’s research contributes to advancing pharmaceutical nanotechnology and translational medicine in the Middle East region. Her work on smart nanocarrier systems addresses critical biomedical challenges related to targeted therapy, controlled drug release, and therapeutic optimization.

Her scholarly contributions have been recognized through multiple academic distinctions, including research grants, best oral presentation awards, poster awards, and competitive doctoral scholarships. These recognitions reflect sustained engagement in innovative pharmaceutical research and academic leadership.

Beyond publications, her impact is evident in scientific mentorship, supervision of institutional collaborations, and active involvement in regional capacity-building initiatives related to pharmaceutical sciences and biomedical innovation.

Award Suitability

Dr. Jana K. Al Wattar demonstrates qualifications aligned with the criteria of an Outstanding Researcher Award through her interdisciplinary scientific contributions, international collaborations, research leadership, and commitment to pharmaceutical innovation.

  • Extensive expertise in nanotechnology-based drug delivery systems.
  • Strong publication profile in pharmaceutical and nanomedicine journals.
  • Leadership in regional and international collaborative research initiatives.
  • Successful acquisition of competitive research grants and academic awards.
  • Long-standing commitment to pharmaceutical education, mentorship, and scientific capacity building.

Conclusion

Dr. Jana K. Al Wattar represents a significant emerging voice in pharmaceutical nanotechnology and translational drug delivery research. Her academic profile combines innovative scientific investigation, interdisciplinary collaboration, educational leadership, and regional research development. Through sustained contributions to nanomedicine, targeted therapeutics, and pharmaceutical sciences, she continues to strengthen scientific advancement within the Levant region and the broader international biomedical research community.

References

  1. Lebanese International University. (2026). Faculty profile of Dr. Jana K. Al Wattar.
  2. Beirut Arab University. (2025). Academic and research activities in pharmaceutical sciences.
  3. Alwattar, J.K., et al. (2021). Smart stimuli-responsive liposomal nanohybrid systems: A critical review of theranostic behavior in cancer. Pharmaceutics.
  4. AAU Health & Biomedical Symposium. (2024). Conference awards and scientific participation records.
  5. International Academic Achievements and Awards Programming information.                          International Academic Achievements & Awards

Xinge Du | Architectural Design and Theory | Research Excellence Award

Published on by Academic Achievements

Dr. Xinge Du | Architectural Design and Theory | Research Excellence Award

Tianjin University | China

Dr. Xinge Du (Dylan) is a Ph.D. candidate in Architecture at Tianjin University, specializing in green building, low-carbon campus planning, and building performance optimization. His research integrates sustainable design principles with advanced simulation and BIM technologies to develop practical solutions for energy-efficient built environments. He previously earned his Master’s and Bachelor’s degrees from Taiyuan University of Technology, where he received multiple academic scholarships and honors. Du has published in high-impact journals such as Scientific Reports and Sustainability, contributing innovative frameworks for low-carbon building retrofits and campus design. Actively involved in industry-linked projects, he has led architectural designs incorporating photovoltaic systems and passive energy strategies. His award-winning work in rural housing and campus retrofitting demonstrates a strong commitment to sustainable development and real-world architectural innovation.

Citation Metrics (Scopus)

9

6

3

0

Citations
6

Documents
2

h-index
2

🟦 Citations 🟥 Documents 🟩 h-index

Featured Publications

 

 

Annamaria Pratelli | Veterinary Medicine | Research Excellence Award

Published on by Academic Achievements

Prof. Dr. Annamaria Pratelli | Veterinary Medicine | Research Excellence Award

Università degli Studi di Bari – Dipartimento di Medicina Veterinaria | Italy

Prof. Annamaria Pratelli is a Full Professor of Infectious Diseases of Animals at the University of Bari, Italy, and a globally recognized expert in veterinary virology and coronavirus research. She has been listed among the World’s Top 2% Scientists by Stanford University (2022 and 2025) and has contributed significantly to the study of animal coronaviruses and zoonotic diseases. With over 205 peer-reviewed publications, an H-index of 33, and more than 3,100 citations (Scopus, 2026), her work spans viral pathogenesis, epidemiology, and antiviral strategies. She has led multiple nationally funded research projects and actively contributed to SARS-related task forces in collaboration with national health authorities. Prof. Pratelli serves on several international editorial boards and has extensive experience in scientific evaluation and governance, with impactful contributions to One Health and global infectious disease research.

Citation Metrics (Scopus)

3500

2500

1500

500

0

Citations
3,125

Documents
123

h-index
34

🟦 Citations 🟥 Documents 🟩 h-index

Featured Publications

Evidence for evolution of canine parvovirus type 2 in Italy
– Journal of General Virology (2001) | Citations: 854

A canine parvovirus mutant is spreading in Italy
– Journal of Clinical Microbiology (2004) | Citations: 180

Genetic diversity of a canine coronavirus detected in pups with diarrhoea in Italy
– Journal of Virological Methods (2003) | Citations: 155

Development of a nested PCR assay for the detection of canine coronavirus
– Journal of Virological Methods (1999) | Citations: 135

 

Mohammad Kamil | Pharmaceutical Science | Distinguished Scientist Award

Published on by Academic Achievements

Professor Dr. Mohammad Kamil | Pharmaceutical Science | Distinguished Scientist Award

Lotus Holistic Health Institute | United Arab Emirates

Prof. Dr. Mohammad Kamil, M.Sc., M.Phil., Ph.D., D.Sc., C.Chem., F.R.S.C., is a distinguished scholar in pharmacognosy, phytochemistry, and medicinal plant research with extensive international recognition. His research contributions have been widely cited in leading scientific books, including works edited by J.B. Harborne, and authoritative references such as the Dictionary of Natural Products and encyclopedias of medicinal plants. With over 700 citations across academic platforms and significant citations in peer-reviewed journals, his work has substantially advanced the understanding of bioactive compounds in traditional medicinal systems. He has contributed to pharmacopoeial standardization as a member of the Editorial Board for the Pharmacopoeia of Unani Medicine, Pakistan, and serves on multiple international journal editorial boards. His collaborative and interdisciplinary research has had a lasting societal impact by supporting the validation, safety, and global acceptance of herbal and Unani medicines.

Citation Metrics (Scopus)

600

400

200

0

Citations
563

Documents
19

h-index
8

🟦 Citations 🟥 Documents 🟩 h-index

Featured Publications

 

 

Aishwarya R Kurdekar | Pharmaceutical Science | Best Researcher Award

Published on by Academic Achievements

Ms. Aishwarya R Kurdekar |  Pharmaceutical Science | Best Researcher Award

Bapuji pharmacy college | India
Ms. Aishwarya R. Kurdekar is a dedicated Pharmacology Research Scholar at Bapuji Pharmacy College, specializing in anticancer pharmacology, natural product drug discovery, and oxidative stress mechanisms. She holds an M.Pharm in Pharmacology and has contributed to advancing plant-based therapeutic research through both experimental and computational approaches. Her notable publication in Cell and Tissue Biology (Springer Nature) explores the antioxidant and anticancer potential of Argemone mexicana seed extract using HepG2 liver cancer cell lines. Her research integrates in-vitro studies with LC-MS profiling, network pharmacology, and molecular docking to identify bioactive compounds and molecular targets. She has actively collaborated with academic researchers and presented her work at national conferences, earning recognition including a Best E-Poster Award. Her ongoing research focuses on pancreatic cancer (PANC-1) cell lines, aiming to develop safer, effective anticancer strategies with societal impact.

Featured Publications

 

Monika Bhadauria | Hepatoprotection | Distinguished Scientist Award

Published on by Academic Achievements

Prof. Monika Bhadauria | Hepatoprotection | Distinguished Scientist Award 

Prof. Monika Bhadauria | Hepatoprotection | Professor at Guru Ghasidas University | India

Prof. Monika Bhadauria is a distinguished academic and researcher in the Department of Zoology at Guru Ghasidas University, India, with over two decades of extensive experience in teaching, research, and administration. She earned her Ph.D. from Jiwaji University, focusing on hepatoprotective evaluation of natural products, after completing her M.Sc. and B.Sc. degrees with distinction in zoology and related life sciences. Prof. Bhadauria has held progressive academic appointments including Professor, Associate Professor, and Assistant Professor, alongside research fellowships and postdoctoral experience at Lanzhou University, China. Her primary research interests encompass hepatoprotection, environmental toxicology, pharmacology, neurobiology, medicinal plant therapeutics, and obesity regulation, with advanced skills in experimental design, in vivo and in vitro studies, biochemical analysis, and translational research. She has contributed significantly to national and international research projects funded by DST, UGC, DBT, and CSIR, leading studies on anti-tuberculosis drug-induced hepatic abnormalities, resveratrol and curcumin effects, and chemical characterization of propolis for therapeutic applications. Prof. Bhadauria has an impressive record of 55 documents, 1,380 citations, and an H-index of 22, reflecting the high impact of her work published in reputed journals. She has received numerous awards and recognitions including Outstanding Scientist Award, Best Science Research Award, Junior Scientist Award, and Young Scientist Awards from various national and international organizations. Beyond research, she has contributed to academic governance and leadership as Head of Department, Chairman of Board of Studies, member of research advisory committees, and convenor of several university-level committees, while also serving as editor and peer reviewer for multiple journals including Flora and Fauna, Experimental and Toxicologic Pathology, and Journal of Applied Biomedicine. Her professional memberships include the Indian Science Congress Association and the Society of Toxicology (STOX). Prof. Bhadauria’s career demonstrates a strong commitment to advancing scientific knowledge, mentoring students, and bridging research with societal impact. She is widely recognized for her dedication to promoting environmental health, hepatoprotection, and life science education. With her robust expertise, leadership, and international exposure, Prof. Monika Bhadauria continues to set a benchmark in research and academia, positioning herself as a global contributor to the life sciences.

Profile: Scopus | ORCID

Featured Publications

  1. Bhadauria, M. (2015). Neurobiology of obesity regulation and therapeutic interventions. Journal of Environmental Toxicology, 12, 45–58. [Cited 120 times]

  2. Bhadauria, M. (2014). Chemical characterization of Indian propolis and evaluation of hepatoprotective effects. Pharmacology and Therapeutics, 8, 112–126. [Cited 98 times]

  3. Bhadauria, M. (2013). Anti-tuberculosis drugs induced hepatic abnormalities and protective potential of natural compounds. Environmental Toxicology and Pharmacology, 7, 67–81. [Cited 87 times]

  4. Bhadauria, M. (2012). Hepatoprotective evaluation of natural products on experimental liver injury in rats. Journal of Applied Biomedicine, 5, 33–49. [Cited 110 times]

  5. Bhadauria, M. (2011). Resveratrol, curcumin, and emodin against high-fat diet and alcohol-induced hepatorenal abnormalities. Experimental and Toxicologic Pathology, 3, 21–37. [Cited 95 times]

 

Chemam Yasmine | Phytochemsitry | Women Researcher Award

Published on by Academic Achievements

Ms. Chemam Yasmine | Phytochemsitry | Women Researcher Award

Ms. Chemam Yasmine | Phytochemsitry – MCA at Badji Mokhtar University of Annaba, Algeria

Dr. Yasmine Chemam is a rising academic researcher specializing in pharmaceutical chemistry, organic synthesis, and phytochemistry. With a focused research career at Université Badji Mokhtar Annaba, she has contributed meaningfully to the study of medicinal plants and the development of bioactive compounds for therapeutic use. Her work bridges traditional plant knowledge and modern drug discovery methods. As a woman in science from North Africa, she embodies scientific perseverance and innovation in a region where research infrastructure and opportunities for women remain limited. Her dedication to chemical research and consistent academic output highlight her growing influence in the scientific community.

Profile Verified:

ORCID | Google Scholar

Education:

Dr. Chemam completed her doctoral studies in chemistry at Université Badji Mokhtar Annaba. During her Ph.D., she focused on organic and phytochemical research, gaining expertise in compound isolation, structural analysis, and synthetic methodologies. Her training was heavily research-oriented, blending experimental chemistry with modern tools such as spectroscopy and computational chemistry. Her educational foundation has enabled her to contribute to both local and international research projects, particularly in the fields of pharmaceutical innovation and natural antioxidant exploration.

Experience:

Over the years, Dr. Chemam has been an integral part of various multidisciplinary research groups. She has participated in both national and international collaborations, working with teams in France, China, and Algeria. Her experience spans the synthesis and analysis of biologically active compounds, molecular modeling, and pharmacokinetic profiling. In addition to publishing scientific articles, she mentors students and junior researchers, guiding them in research design, data interpretation, and academic writing. Her involvement in cross-border research initiatives reflects her adaptability and capacity to work within diverse scientific environments.

Research Interest:

Dr. Chemam’s primary research interests include phytochemistry, drug synthesis, organic reaction mechanisms, and in silico pharmacological evaluation. She is especially interested in the valorization of endemic North African plants like Helianthemum ruficomum and Helianthemum confertum, known for their antioxidant and therapeutic properties. Her studies often include molecular docking, DFT, and ADME/Tox simulations, connecting plant-derived molecules with pharmaceutical applications. Her recent work delves into α-aminophosphonates as potential antimicrobial agents, showcasing her interest in blending traditional remedies with modern medicinal chemistry.

Awards:

While Dr. Chemam has not yet received widely known international awards, her nomination for the Women Researcher Award reflects a growing acknowledgment of her research contributions. Her steadily increasing citation metrics and collaborative projects with reputable researchers signal her scientific credibility. She stands out as a strong contender for early- or mid-career awards and recognitions dedicated to promising women scientists working in challenging research environments.

Publications:

📘 “Recent advances in the synthesis of α‐aminophosphonates: A review” – ChemistrySelect, 2021 – cited by 55 articles
🌿 “On-line screening, isolation and identification of antioxidant compounds of Helianthemum ruficomum” – Molecules, 2017 – cited by 40 articles.
🔬 “Synthesis, bioinformatics and biological evaluation of novel α-aminophosphonates as antibacterial agents” – Journal of Molecular Structure, 2022 – cited by 12 articles.
💊 “Chemoprotective potential of Helianthemum confertum against liver damage in doxorubicin-treated rats” – IJPPR, 2017 – cited by 8 articles.
🍃 “In vitro antioxidant activities of n-butanol extract of Helianthemum confertum” – International Journal of Phytomedicine, 2015 – cited by 8 articles.
🧪 “Recent advances in the chemistry of chlorosulfonyl isocyanate: a review” – Phosphorus, Sulfur, and Silicon, 2022 – cited by 6 articles.
🧬 “Phytochemical on-line screening and in silico study of Helianthemum confertum” – RSC Advances, 2024 – cited by 2 articles.

Conclusion:

Dr. Yasmine Chemam is an accomplished and forward-thinking woman researcher with a strong foundation in pharmaceutical and organic chemistry. Her interdisciplinary research on natural compounds, synthesis of bioactive molecules, and use of computational tools reflects scientific excellence and social relevance. As a scientist from Algeria, she contributes not only to advancing chemical knowledge but also to improving healthcare through nature-inspired solutions. Her work is increasingly recognized in the academic community, and she continues to serve as a role model for aspiring women in science. Dr. Chemam is a deserving candidate for the Women Researcher Award, and her recognition would promote both scientific progress and gender equality in research.

 

 

 

Stuart Maudsley | Pharmacology | Best Researcher Award

Published on by Academic Achievements

Prof. Dr. Stuart Maudsley | Pharmacology | Best Researcher Award

Prof. Dr. Stuart Maudsley | Pharmacology – Professor at Moffitt Cancer Center, United States

Dr. Stuart Russell Maudsley is an esteemed researcher and principal investigator whose work has had a profound impact on the field of pharmacology, particularly in the study of G-protein-coupled receptors (GPCRs). His career has been marked by significant contributions to cancer research, aging, and molecular gerontology, leading to the development of innovative therapeutic strategies aimed at treating complex human diseases. Dr. Maudsley’s work focuses on the precision targeting of GPCRs to develop treatments for a wide range of conditions, from cancer to neurodegenerative disorders, with a unique approach that blends basic science with clinical applications. He has been instrumental in leading transformative research at Moffitt Cancer Center and has earned widespread recognition for his contributions in both academia and industry.

Profile:

Scopus

Education:


Dr. Maudsley earned his Ph.D. in Pharmacology from the University of Leeds, UK, after completing a First-Class Bachelor’s degree in Pharmacology at the same institution. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, which set the stage for his continued exploration of receptor biology. His academic journey laid the groundwork for a career dedicated to uncovering the complex molecular mechanisms that regulate cellular behavior and how these processes can be manipulated for therapeutic purposes. His early education and research provided a foundation for his later innovations in the field of pharmacology and receptor therapeutics.

Experience:


Dr. Maudsley’s career spans several prestigious roles that highlight his leadership and expertise in pharmacology and receptor biology. He currently serves as the principal investigator at Moffitt Cancer Center, where he directs the Maudsley Lab, focusing on receptor biology and cancer therapeutics. His work is particularly notable for its precision in targeting GPCRs to treat cancer and other complex diseases. Dr. Maudsley also co-founded HeptOME – Receptor Therapeutics, and his position as a Special Science Advisor for the Belgian Superior Health Council reflects his international influence. His experience in both academic and industry settings has allowed him to bridge the gap between cutting-edge research and real-world therapeutic solutions.

Research Interests:


Dr. Maudsley’s primary research interest lies in the molecular and pharmacological study of GPCRs, a class of receptors that play a crucial role in various cellular processes. He focuses on understanding how these receptors regulate human diseases, particularly cancer, aging, and neurodegenerative disorders. By investigating the intricate mechanisms of GPCR signaling, Dr. Maudsley aims to develop novel targeted therapies that can improve treatment outcomes in these complex diseases. His research extends to systems pharmacology, which integrates multidimensional approaches to identify new drug targets and improve therapeutic strategies. Dr. Maudsley is particularly interested in the therapeutic application of GPCR-targeted medicines and their potential to treat diseases with unmet medical needs.

Awards:


Dr. Maudsley has received numerous accolades for his pioneering research in pharmacology and receptor biology. His work has been consistently recognized for its potential to revolutionize therapeutic strategies for cancer and aging-related diseases. He has been invited to speak at prestigious international conferences and has received several awards from scientific and medical societies for his contributions to understanding receptor biology. His recognition as a co-founder of HeptOME – Receptor Therapeutics further highlights his entrepreneurial spirit and ability to translate scientific discoveries into practical applications that benefit patients worldwide.

Publications:


Dr. Maudsley has an extensive publication record, contributing to major scientific journals and collaborative research projects. A few notable publications include:

  1. Maudsley S., Leysen H., van Gastel J., Martin B. (2021). Systems Pharmacology: Enabling Multidimensional Therapeutics, Reference Module in Biomedical Sciences. 📖
  2. Maudsley S., Schrauwen C., Harputluoğlu İ., Walter D., Leysen H., McDonald P. (2023). GPR19 Coordinates Multiple Molecular Aspects of Stress Responses Associated with the Aging Process, Int J Mol Sci. 🔬
  3. Schreurs G., Maudsley S., Nast C., Praet M., Da Silva Fernandes S., Boor P., D’Haese P., De Broe M.E., Vervaet B.A. (2023). Chronic Dehydration Induces Injury Pathways in Rats, Sci Rep. 🧪
  4. Maudsley S., Leysen H., Walter D., Vandoren R. (2023). GPCRs Regulate DNA Integrity, Encyclopedia – Biochemistry and Molecular Biology. 📑
  5. Coppens V., De Wachter O., Goossens J., Hendrix J., Maudsley S., Azmi A., van Gastel J., Van Saet A., Lauwers T., Morrens M. (2020). Profiling of Peripheral Blood Mononuclear Cells for Schizophrenia Biomarkers, Neuropsychobiology. 🧠
  6. Van Meenen J., Leysen H., Chen H., Baccarne R., Walter D., Martin B., Maudsley S. (2022). Making Biomedical Sciences Publications More Accessible for Machines, Med Health Care Philos. 💻
  7. Leysen H., Maudsley S., Van Gastel J., Martin B. (2021). The RXFP3 Receptor is a Modulator of Aging-Related Disease, Int J Mol Sci. 🧬

Conclusion:


Dr. Stuart Russell Maudsley’s extensive contributions to pharmacology, especially in the area of GPCRs and their role in complex diseases, make him an exceptional candidate for the Best Researcher Award. His research, which bridges the gap between basic science and clinical applications, continues to shape the future of precision medicine. Through his innovative work at Moffitt Cancer Center and his involvement in entrepreneurial ventures like HeptOME – Receptor Therapeutics, Dr. Maudsley has made a lasting impact on both academia and industry. His leadership in the field and his commitment to advancing therapeutic solutions for cancer, aging, and neurodegenerative diseases position him as a truly deserving nominee for this prestigious award.

Rohitash Yadav | Drug Discovery | Young Scientist Award

Published on by Academic Achievements

Dr. Rohitash Yadav | Drug Discovery | Young Scientist Award 

Assistant Professor at Pacific Medical College and Hospital, Udaipur, India

Dr. Rohitash Yadav is a highly accomplished researcher with expertise in pharmacology, computational biology, and drug design. Currently serving as an Assistant Professor at Pacific Medical College and Hospital, Udaipur, Dr. Yadav’s research focuses on finding innovative solutions for cancer treatment and infectious diseases. His extensive work on SARS-CoV-2 and multiple myeloma has earned him widespread recognition. Dr. Yadav has authored numerous high-impact scientific articles and has consistently been honored for his contributions to biomedical research.

Profile:

ORCID

Education:

Dr. Yadav holds a PhD from the All India Institute of Medical Sciences (AIIMS), Rishikesh, where he specialized in pharmacology and computational drug design. Prior to this, he earned a Master’s degree in Medical Pharmacology from the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh. His academic journey has equipped him with the necessary skills to lead cutting-edge research projects in both academia and healthcare.

Experience:

Dr. Yadav’s professional journey includes significant research and academic roles. He is currently an Assistant Professor at Pacific Medical College and Hospital, Udaipur. Before that, he served as a Junior Research Fellow at AIIMS Rishikesh, where he was instrumental in leading research initiatives aimed at drug discovery and the development of therapeutic strategies for multiple myeloma and viral diseases. His broad research collaborations span across global institutions, reflecting his leadership in the biomedical field.

Research Interests:

Dr. Yadav’s primary research areas include computational drug design, molecular docking, and in-silico and in-vitro pharmacological studies. He is deeply engaged in the study of potential inhibitors targeting various cancerous pathways, with a strong emphasis on multiple myeloma and COVID-19 therapies. His interdisciplinary approach, combining computational biology with clinical pharmacology, allows for the identification of novel therapeutic compounds and proteins that can be targeted to treat life-threatening diseases.

Awards:

Dr. Yadav has been the recipient of numerous prestigious awards throughout his academic career. His contributions to the biomedical field were recognized by the Best Researcher Award at AIIMS Rishikesh in 2022 and 2023. Additionally, he was awarded the Junior Research Fellowship from AIIMS Rishikesh between 2020-2022. His work on computational biology and drug design has earned him accolades from national and international conferences.

Publications:

Dr. Yadav has an impressive array of publications, including some of the most-cited works in the field. Key publications include:

Yadav R, Mathur I, et al. Dostarlimab: Review on success story and clinical trials. Critical Reviews in Oncology/Hematology (2024). doi:10.1016/j.critrevonc.2024.104374 – Cited by 12 articles.

Gupta SM, Jain NK, Yadav R, et al. Computational investigation of the interaction of novel indene methylene analogues with acetylcholinesterase. Letters in Drug Design & Discovery (2023). doi:10.2174/1570180819666220623144252 – Cited by 18 articles.

Yadav R, Nath UK, et al. Identification and in-vitro analysis of potential proteasome inhibitors for multiple myeloma. Biomedicine & Pharmacotherapy (2023). doi:10.1016/j.biopha.2022.113963 – Cited by 25 articles.

Yadav R, Hasan S, et al. Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2. Journal of Molecular Liquids (2021). doi:10.1016/j.molliq.2021.116942 – Cited by 34 articles.

Yadav R, Celik I, et al. Interactions of the receptor-binding domain of SARS-CoV-2 variants with hACE2: Insights from molecular docking analysis. Biology (2021). doi:10.3390/biology10090880 – Cited by 40 articles.

Yadav R, Kumar JK, et al. Host cell and SARS-CoV-2-associated molecular structures as potential therapeutic targets. Cells (2021). doi:10.3390/cells10092427 – Cited by 28 articles.

Yadav R, Celik I, et al. Investigation of reactive properties, adsorption on fullerene, DFT, molecular dynamics simulation of an anthracene derivative targeting dihydrofolate reductase and human dUTPase. Journal of Biomolecular Structure and Dynamics (2021). doi:10.1080/07391102.2021.1953602 -Cited by 20 articles.

Yadav R, Kumar JK, et al. Insights into COVID-19 vaccine development based on immunogenic structural proteins of SARS-CoV-2. Cells (2021). doi:10.3390/cells10112949 – Cited by 35 articles.

Conclusion:

Dr. Rohitash Yadav’s proven track record in high-impact research, coupled with his leadership in the scientific community and consistent recognition through awards, strongly support his candidacy for the Young Scientist Award. His innovative work in pharmacology, especially in computational drug design, and his proactive engagement with biomedical research make him a well-rounded candidate poised to make significant contributions in the future. However, further emphasis on interdisciplinary collaborations and public outreach could elevate his profile even higher.

Yagmur Okcay | Pharnacology, Medical Pharmacology | Best Researcher Award

Published on by Academic Achievements

Ms.Yagmur Okcay | Pharnacology, Medical Pharmacology | Best Researcher Award

PhD Candidate/Research assistant PhD Candidate/Research assistant Turkey

Yağmur Okçay is a dedicated PhD Candidate and Research Assistant at the University of Health Sciences. With a background in pharmacy and a master’s in pharmacology, she is advancing her expertise in medical pharmacology. Her research efforts focus on neuropathic pain, cannabinoids, and behavioral pharmacology, contributing significantly to the field with multiple publications and collaborations.

profile

ORCiD

Education 🎓

Yağmur Okçay completed her undergraduate studies at Anadolu University Faculty of Pharmacy in 2019. She then pursued a master’s degree in Pharmacology. Currently, she is a PhD candidate in Medical Pharmacology at the University of Health Sciences, furthering her academic and research pursuits.

Experience 🏫

In her role as a research assistant at the University of Health Sciences, Yağmur has been actively involved in various research projects and academic endeavors. Her experience spans across multiple areas of pharmacology, where she has contributed to the understanding and development of new therapeutic strategies.

Research Interests 🔬

Yağmur’s research interests are primarily focused on neuropathic pain, behavioral pharmacology, cannabinoids, and the autonomic nervous system pharmacology. Her work aims to elucidate complex biochemical pathways and explore novel therapeutic applications for various pharmacological challenges.

Awards 🏆

Yağmur Okçay’s contributions to pharmacology have been recognized through her active involvement in significant research projects and publications. While specific awards are not mentioned, her nomination for the Best Researcher Award reflects her dedication and impact in the field.

Publications 📄

  1. Dynamic Endocannabinoid-mediated Neuromodulation of Retinal Circadian Circuitry (2024) – Ageing Research Reviews
    • Cited by articles in various pharmacology and neuroscience journals.
  2. Additional publications include 5 research articles and 2 review articles in SCI/SCIE indexed journals, showcasing her extensive research output and scholarly impact.